In “SuPerTreat” project an actionable personalized treatment decisions support system (CDSS) for cancer will be built. This will happen via the development and validation of in-silico new, powerful Big Data driven Artificial Intelligence (AI) methods. The focus will be on Head and Neck Cancer (HNC), which poses many therapeutic challenges due to its heterogeneity and aggressiveness, for which the Consortium has internationally recognized wide expertise. Also, the project integrates ethical dimensions for novel approaches in personalized medicine and will model personalized disease prediction of recurrence to orient therapeutic decisions at diagnosis by predicting outcomes, and by assessing the role of individual and combined biomolecular, clinical and lifestyle factors as related to different treatment options.
SuPerTreat is a collaboration between 6 partners from 5 countries: Università degli Studi di Milano – UMIL (Italy) that is coordinating the project, Charité – Universitaetsmedizin Berlin – CHARITE (Germany), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – INT (Italy), University of Oslo – UiO (Norway), Institut Curie – Paris & Saint-Cloud (France) and Athens Technology Center S.A. (Greece).
ATC, will lead the actions for the development of a Personalized Clinical Decision Support System, focusing on developing Data visualization tools and Clinical Collaborative Decision Support Systems.
SuPerTreat is funded under the ERA PerMed Joint Transnational Call 2019 Personalised Medicine: Multidisciplinary Research Towards Implementation. The project started in September 2020 and has a duration of 36 months.
